Company profile: GT Biopharma
1.1 - Company Overview
Company description
- Provider of TriKE immunotherapy technology that bridges natural killer cells to cancer cells to boost anti-tumor responses. Pipeline includes GTB-3550 for CD33+ leukemias (AML, high-risk MDS), GTB-3650 using camelid nanobodies for CD33+ leukemias, and GTB-5550, GTB-4550, GTB-6550 for B7H3, PD-L1, and HER2 positive solid tumors.
Products and services
- TriKE® Technology: Platform-based immunotherapeutic architecture that creates agents bridging natural killer cells to cancer cells to enhance anti-tumor immune activity via targeted NK cell engagement
- GTB-3650: Camelid nanobody-based TriKE product candidate targeting CD33-positive leukemias, including AML and MDS, engineered to enhance NK-cell-mediated tumor elimination
- GTB-3550: First-generation TriKE product candidate for CD33-positive leukemias, including AML and high-risk MDS, developed to bridge NK cells to malignant cells and amplify anti-tumor immunity
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to GT Biopharma
Valo Therapeutics
HQ: Finland
Website
- Description: Provider of immuno-oncology platforms developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. Offerings include PeptiCRAd (oncolytic adenoviruses plus tumor-specific peptides), PeptiENV (oncolytic enveloped viruses with peptides), PeptiVAX (peptide-based cancer vaccines), PeptiBAC (bacteria delivering tumor peptides), and PeptiCHIP (microchip-based tumor neoantigen identification).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Valo Therapeutics company profile →
Vical
HQ: United States
Website
- Description: Provider of biopharmaceutical product research and development based on its patented DNA delivery technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vical company profile →
VaxGen
HQ: United States
Website
- Description: Provider of biopharmaceutical products in the United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full VaxGen company profile →
BriaCell Therapeutics
HQ: United States
Website
- Description: Provider of immuno-oncology therapeutics developing targeted approaches for cancer management, including Bria-IMT™, a cell-based immunotherapy for advanced metastatic breast cancer that stimulates the immune system to target and kill cancer cells, and Bria-OTS™, a personalized off-the-shelf immunotherapy for advanced breast cancer engineered to match patients' HLA types.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BriaCell Therapeutics company profile →
SuppreMol
HQ: Germany
Website
- Description: Provider of biotechnology therapies pioneering a novel approach to treat autoimmune diseases, aiming to cure these disorders rather than merely manage symptoms; privately held.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SuppreMol company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for GT Biopharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to GT Biopharma
2.2 - Growth funds investing in similar companies to GT Biopharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for GT Biopharma
4.2 - Public trading comparable groups for GT Biopharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →